Skip to main content

Pazopanib: A Review of Its Use in the Management of Advanced Renal Cell Carcinoma

Abstract

Pazopanib (Votrient®) is an orally administered multi-tyrosine kinase inhibitor that is approved in the EU, the US and other countries for the treatment of advanced renal cell carcinoma. Pazopanib predominantly inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet-derived growth factor receptor-α and -β, and the stem cell factor receptor c-Kit, resulting in inhibition of tumour angiogenesis, cell growth and survival. In randomized controlled trials in patients with advanced, predominantly clear-cell, renal cell carcinoma, progression-free survival (PFS) and the objective response rate were significantly greater in pazopanib recipients than in placebo recipients (VEG105192 trial), and pazopanib was noninferior to sunitinib with respect to PFS (COMPARZ study). In a patient-preference, crossover study involving 10 weeks of treatment with each drug (PISCES study), significantly more patients expressed a preference for pazopanib than for sunitinib, with their preference being based primarily on tolerability and quality-of-life issues. Health-related quality-of-life (HR-QOL) assessments generally favoured pazopanib over sunitinib in COMPARZ, and pazopanib did not cause deterioration in HR-QOL compared with placebo in VEG105192. Pazopanib caused less myelosuppression, hand-foot syndrome, mucositis/stomatitis, dysgeusia and fatigue than sunitinib, but more abnormal liver function tests. Therefore, pazopanib was noninferior to sunitinib with respect to efficacy in the treatment of advanced renal cell carcinoma, but had a differentiated tolerability profile, which affected HR-QOL and patient preference.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014. http://globocan.iarc.fr/. Accessed 20 May 2014.

  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75.

    CAS  PubMed  Article  Google Scholar 

  3. Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.

    PubMed  Article  Google Scholar 

  4. Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma. 2013. http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LRV2.pdf. Accessed 20 May 2014.

  5. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs. 2011;71(9):1179–91.

    CAS  PubMed  Article  Google Scholar 

  6. Zacchia M, Vilasi A, Capasso A, et al. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol. 2011;24(2):155–64.

    CAS  PubMed  Article  Google Scholar 

  7. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8(6):779–90.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  8. Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology. 2011;78(2):90–8.

    PubMed Central  PubMed  Article  Google Scholar 

  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (version 3.2014). 2014. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 22 May 2014.

  10. Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65–71.

    PubMed  Article  Google Scholar 

  11. European Medicines Agency. Votrient (pazopanib) 200 mg film-coated tablet: summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf. Accessed 20 May 2014.

  12. GlaxoSmithKline. Votrient (pazopanib) tablets: US prescribing information. 2013. http://us.gsk.com/products/assets/us_votrient.pdf. Accessed 20 May 2014.

  13. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011;71(4):443–54.

    CAS  PubMed  Google Scholar 

  14. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012–21.

    CAS  PubMed  Article  Google Scholar 

  15. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101(10):1717–23.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  16. Canter D, Kutikov A, Golovine K, et al. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol. 2011;18(4):5819–25.

    PubMed Central  PubMed  Google Scholar 

  17. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827–37.

    CAS  PubMed  Article  Google Scholar 

  18. Xu C-F, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011;29(18):2557–64.

    CAS  PubMed  Article  Google Scholar 

  19. Xu C-F, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54(6):1237–43.

    CAS  PubMed  Article  Google Scholar 

  20. Xu C-F, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102(9):1371–7.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  21. Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(6):818–23.

    CAS  PubMed  Article  Google Scholar 

  22. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220–7.

    CAS  PubMed  Article  Google Scholar 

  23. FDA Center for Drug Evaluation and Research. Votrient (pazopanib) hydrochloride tablets: clinical pharmacology and biopharmaceutics review(s). 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf. Accessed 20 May 2014.

  24. Xu C-F, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012;23(9):2470–1.

    CAS  PubMed  Article  Google Scholar 

  25. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    CAS  PubMed  Article  Google Scholar 

  26. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412–8.

    PubMed  Article  Google Scholar 

  27. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.

    CAS  PubMed  Article  Google Scholar 

  28. Sanford M, Keating GM. Pazopanib: in advanced renal cell carcinoma. BioDrugs. 2010;24(5):279–86.

    CAS  PubMed  Article  Google Scholar 

  29. Hutson TE, Davis ID, Machiels J-PH, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28(3):475–80.

    CAS  PubMed  Article  Google Scholar 

  30. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–96.

    CAS  PubMed  Article  Google Scholar 

  31. Hawkins RE, Hong SJ, Ulys A, et al. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) [abstract no. 5110]. J Clin Oncol. 2009;27(15 Suppl).

  32. Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769–70.

    CAS  PubMed  Article  Google Scholar 

  33. Cella D, Pickard AS, Duh MS, et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer. 2012;48(3):311–23.

    CAS  PubMed  Article  Google Scholar 

  34. Goodman V, Wang K, Pandite L, et al. Incidence and management of hepatic toxicity in pazopanib-treated patients [abstract no. 904P]. Ann Oncol. 2010;21(Suppl 8):viii282.

    Google Scholar 

  35. Lim FL, Shamash J, Wilson P, et al. Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy [abstract no. 880]. Ann Oncol. 2012;23(Suppl 9):ix290.

    Google Scholar 

  36. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 20 May 2014.

  37. Pal SK, Vanderwalde A, Hurria A. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging. 2011;28(8):635–49.

    CAS  PubMed  Article  Google Scholar 

  38. Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alfa therapy. Pharm World Sci. 2005;27(6):423–31.

    CAS  PubMed  Article  Google Scholar 

  39. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  40. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.

    PubMed  Article  Google Scholar 

  41. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  42. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    CAS  PubMed  Article  Google Scholar 

  43. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    CAS  PubMed  Article  Google Scholar 

  44. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    CAS  PubMed  Article  Google Scholar 

  45. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.

    CAS  PubMed  Article  Google Scholar 

  46. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal cancer Global Evaluation Trial. J Clin Oncol. 2009;27(20):3312–8.

    CAS  PubMed  Article  Google Scholar 

  47. McCann L, Amit O, Pandite L, et al. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC) [abstract no. e15128]. J Clin Oncol. 2010;28(15 Suppl).

  48. Mickisch GH, Schwander B, Escudier BJ, et al. Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy [abstract no. 4612]. J Clin Oncol. 2010;28(15 Suppl).

  49. Garnick MB. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job? J Clin Oncol. 2014;32(14):1392–3.

    PubMed  Article  Google Scholar 

  50. Kilonzo M, Hislop J, Elders A, et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31:15–24.

    PubMed  Article  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Paul McCormack is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul L. McCormack.

Additional information

The manuscript was reviewed by: L. Bergmann, Medical Clinic II, Department of Internal Medicine, Goethe University Hospital, Frankfurt, Germany; D. Cella, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Evanston, IL, USA.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McCormack, P.L. Pazopanib: A Review of Its Use in the Management of Advanced Renal Cell Carcinoma. Drugs 74, 1111–1125 (2014). https://doi.org/10.1007/s40265-014-0243-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0243-3

Keywords

  • Renal Cell Carcinoma
  • Sorafenib
  • Sunitinib
  • National Comprehensive Cancer Network
  • Metastatic Renal Cell Carcinoma